701. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.
- Author
-
Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, van der Vaart T, Jansen FE, Elgersma Y, Moll HA, and de Wit MY
- Subjects
- Adolescent, Autistic Disorder etiology, Autistic Disorder psychology, Child, Communication, Double-Blind Method, Executive Function, Female, Humans, Intellectual Disability etiology, Intelligence Tests, Male, Problem Behavior, Quality of Life, Sleep, Social Behavior, Tuberous Sclerosis complications, Tuberous Sclerosis psychology, Autistic Disorder drug therapy, Everolimus therapeutic use, Immunosuppressive Agents therapeutic use, Intellectual Disability drug therapy, TOR Serine-Threonine Kinases antagonists & inhibitors, Tuberous Sclerosis drug therapy
- Abstract
Objective: To investigate whether mammalian target of rapamycin inhibitor everolimus can improve intellectual disability, autism, and other neuropsychological deficits in children with tuberous sclerosis complex (TSC)., Methods: In this 12-month, randomized, double-blind, placebo-controlled trial, we attempted to enroll 60 children with TSC and IQ <80, learning disability, special schooling, or autism, aged 4-17 years, without intractable seizures to be assigned to receive everolimus or placebo. Everolimus was titrated to blood trough levels of 5-10 ng/mL. Primary outcome was full-scale IQ; secondary outcomes included autism, neuropsychological functioning, and behavioral problems., Results: Thirty-two children with TSC were randomized. Intention-to-treat analysis showed no benefit of everolimus on full-scale IQ (treatment effect -5.6 IQ points, 95% confidence interval -12.3 to 1.0). No effect was found on secondary outcomes, including autism and neuropsychological functioning, and questionnaires examining behavioral problems, social functioning, communication skills, executive functioning, sleep, quality of life, and sensory processing. All patients had adverse events. Two patients on everolimus and 2 patients on placebo discontinued treatment due to adverse events., Conclusions: Everolimus did not improve cognitive functioning, autism, or neuropsychological deficits in children with TSC. The use of everolimus in children with TSC with the aim of improving cognitive function and behavior should not be encouraged in this age group., Clinicaltrialsgov Identifier: NCT01730209., Classification of Evidence: This study provides Class I evidence that for children with TSC, everolimus does not improve intellectual disability, autism, behavioral problems, or other neuropsychological deficits., (© 2019 American Academy of Neurology.)
- Published
- 2019
- Full Text
- View/download PDF